Alector, Inc.
ALEC · NASDAQ
Market closed$1.50$0.030000 (+2.04%)After hours $1.50 · 0.00%
Key statistics
Previous close$1.47
Open$1.46
Day high$1.52
Day low$1.43
52-week high$3.40
52-week low$1.09
Market cap166.54M
Volume493.11K
Average volume727.03K
P/E ratio-1.26
Forward P/E—
EPS-1.19
Dividend yield0.00%
Market context
Why it moved
ALEC shares edged higher amid modest buying interest, likely supported by a slight recovery from its year-to-date decline, as broader market volatility driven by AI sector sell-offs and rising oil prices did not significantly weigh on the small-cap biotech stock.
What is happening
Recent company-specific developments and publisher coverage.
Fierce Biotech · July 9, 2026GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failurespharmaphorum · March 5, 2026Alector ditches GSK-partnered dementia drug and cuts staffBioSpace · October 22, 2025Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of StaffBioPharma Dive · October 22, 2025Alector dementia drug, partnered with GSK, fails in key study Benzinga · July 10, 2026GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership Benzinga · May 7, 2026Alector Launches Up To $125M At-The-Market Common Stock Offering Through TD Cowen Benzinga · May 7, 2026Alector Q1 EPS $(0.21) Beats $(0.35) Estimate, Sales $1.046M Miss $6.207M Estimate Mt Newswire · April 15, 2026Cantor Fitzgerald Upgrades Alector to Overweight From Neutral Mt Newswire · March 12, 2026Alector Files $400 Million Mixed Shelf Benzinga · March 12, 2026Alector Files Prospectus To Offer Up To $400M In Common Stock Mt Newswire · March 10, 2026Alector Shares Rise After BTIG Upgrade Benzinga · March 10, 2026BTIG Upgrades Alector to Buy, Announces $6 Price Target